BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

about

The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis.Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

P2860

Q49718931-03D17A04-42AA-418B-A096-4CDCA3E34F84 Q58806326-B4BB6639-5F5B-44B7-954F-CD61A52651BE

P2860

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

Item

http://www.wikidata.org/entity/Q47767987

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@en

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@nl

type

Item

label

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@en

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@nl

prefLabel

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@en

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@nl

P1476

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

@en

P2093

E Elez

http://www.w3.org/2001/XMLSchema#string

E Sanz-Garcia

http://www.w3.org/2001/XMLSchema#string

G Argiles

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular characterization of human colon and rectal cancer

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

P304

2648-2657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX401

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29045527

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

about

P2860

P2860

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921